Literature DB >> 21411548

Implications of early menopause in women exposed to perfluorocarbons.

Sarah S Knox1, Timothy Jackson, Beth Javins, Stephanie J Frisbee, Anoop Shankar, Alan M Ducatman.   

Abstract

CONTEXT: Perfluorocarbons (PFC) are man-made chemicals used in numerous household products. They have a long half-life in humans and complex animal toxicity, and accumulating evidence points toward associations with multiple human health endpoints.
OBJECTIVE: Our objective was to investigate whether PFC are associated with endocrine disruption in women.
DESIGN: Cross-sectional analyses were made between quintiles of serum PFC, serum estradiol, and menopause onset.
SETTING: The C8 Health Project, with cohort of 69,030 adults and children, was conducted due to PFC contamination of drinking water from six water districts in two states. PARTICIPANTS: Participants included 25,957 women aged 18-65 yr. MAIN OUTCOME MEASURES: Serum estradiol levels and onset of menopause were assessed. The survey was the result of a class action suit, and survey designers (an independent corporation) had no a priori hypotheses. All hypotheses have been formulated by other investigators after data collection.
RESULTS: After excluding women who reported hysterectomy and adjusting for age within the group, smoking, alcohol consumption, body mass index, and exercise, the odds of having experienced menopause were significantly higher in the highest quintile relative to the lowest quintile of perfluorooctanoate (PFOA) and perfluorooctane sulfonate (PFOS) in the perimenopausal [PFOS odds = 1.4, confidence interval (CI) = 1.1-1.8; PFOA odds =1.4, CI = 1.1-1.8] and menopausal age groups (PFOS odds = 2.1, CI=1.6-2.8; PFOA odds = 1.7, CI = 1.3-2.3). After appropriate exclusions and adjustment for covariates, there was a significant inverse association between PFOS and estradiol in perimenopausal (β = -3.65; P < 0.0001) and menopausal age groups (β = -0.83; P = 0.007) but not between PFOA and estradiol.
CONCLUSIONS: These data suggest that PFC are associated with endocrine disruption in women and that further research on mechanisms is warranted.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21411548      PMCID: PMC3206400          DOI: 10.1210/jc.2010-2401

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  23 in total

Review 1.  Early ovarian ageing.

Authors:  D Nikolaou; A Templeton
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2004-04-15       Impact factor: 2.435

Review 2.  Immunotoxicity of perfluorooctanoic acid and perfluorooctane sulfonate and the role of peroxisome proliferator-activated receptor alpha.

Authors:  Jamie C DeWitt; Alexander Shnyra; Mostafa Z Badr; Scott E Loveless; Denise Hoban; Steven R Frame; Robyn Cunard; Stacey E Anderson; B Jean Meade; Margie M Peden-Adams; Robert W Luebke; Michael I Luster
Journal:  Crit Rev Toxicol       Date:  2009       Impact factor: 5.635

3.  Endogenous estrogen exposure and cardiovascular mortality risk in postmenopausal women.

Authors:  Miriam J J de Kleijn; Yvonne T van der Schouw; André L M Verbeek; Petra H M Peeters; Jan-Dirk Banga; Yolanda van der Graaf
Journal:  Am J Epidemiol       Date:  2002-02-15       Impact factor: 4.897

4.  Chronic exposure to perfluorododecanoic acid disrupts testicular steroidogenesis and the expression of related genes in male rats.

Authors:  Zhimin Shi; Lina Ding; Hongxia Zhang; Yixing Feng; Muqi Xu; Jiayin Dai
Journal:  Toxicol Lett       Date:  2009-05-03       Impact factor: 4.372

5.  The effect of perfluorododecanonic acid on endocrine status, sex hormones and expression of steroidogenic genes in pubertal female rats.

Authors:  Zhimin Shi; Hongxia Zhang; Lina Ding; Yixing Feng; Muqi Xu; Jiayin Dai
Journal:  Reprod Toxicol       Date:  2009-02-25       Impact factor: 3.143

Review 6.  Premature menopause increases cardiovascular risk.

Authors:  D F Archer
Journal:  Climacteric       Date:  2009       Impact factor: 3.005

Review 7.  Toxicity and toxicokinetics of perfluorooctanoic acid in humans and animals.

Authors:  Naomi Kudo; Yoichi Kawashima
Journal:  J Toxicol Sci       Date:  2003-05       Impact factor: 2.196

Review 8.  Emerging endocrine disrupters: perfluoroalkylated substances.

Authors:  Allan Astrup Jensen; Henrik Leffers
Journal:  Int J Androl       Date:  2008-04

9.  Effects of ammonium perfluorooctanoate on Leydig cell function: in vitro, in vivo, and ex vivo studies.

Authors:  L B Biegel; R C Liu; M E Hurtt; J C Cook
Journal:  Toxicol Appl Pharmacol       Date:  1995-09       Impact factor: 4.219

10.  Accumulation and clearance of perfluorooctanoic acid (PFOA) in current and former residents of an exposed community.

Authors:  Ryan Seals; Scott M Bartell; Kyle Steenland
Journal:  Environ Health Perspect       Date:  2010-09-22       Impact factor: 9.031

View more
  45 in total

1.  Histopathologic changes in the uterus, cervix and vagina of immature CD-1 mice exposed to low doses of perfluorooctanoic acid (PFOA) in a uterotrophic assay.

Authors:  Darlene Dixon; Casey E Reed; Alicia B Moore; Eugene A Gibbs-Flournoy; Erin P Hines; Elizabeth A Wallace; Jason P Stanko; Yi Lu; Wendy N Jefferson; Retha R Newbold; Suzanne E Fenton
Journal:  Reprod Toxicol       Date:  2011-11-28       Impact factor: 3.143

2.  Serum perfluoroalkyl acids (PFAAs) and associations with behavioral attributes.

Authors:  Rebecca Siebenaler; Rochelle Cameron; Craig M Butt; Kate Hoffman; Christopher P Higgins; Heather M Stapleton
Journal:  Chemosphere       Date:  2017-06-09       Impact factor: 7.086

3.  Perfluoroalkyl and polyfluoroalkyl substances (PFAS) and their effects on the ovary.

Authors:  Ning Ding; Siobán D Harlow; John F Randolph; Rita Loch-Caruso; Sung Kyun Park
Journal:  Hum Reprod Update       Date:  2020-09-01       Impact factor: 15.610

4.  Early life exposure to endocrine-disrupting chemicals causes lifelong molecular reprogramming of the hypothalamus and premature reproductive aging.

Authors:  Andrea C Gore; Deena M Walker; Aparna M Zama; AnnMarie E Armenti; Mehmet Uzumcu
Journal:  Mol Endocrinol       Date:  2011-10-20

5.  Decline in perfluorooctane sulfonate and perfluorooctanoate serum concentrations in an Australian population from 2002 to 2011.

Authors:  L-M L Toms; J Thompson; A Rotander; P Hobson; A M Calafat; K Kato; X Ye; S Broomhall; F Harden; J F Mueller
Journal:  Environ Int       Date:  2014-06-27       Impact factor: 9.621

6.  Associations of Perfluoroalkyl Substances with Incident Natural Menopause: The Study of Women's Health Across the Nation.

Authors:  Ning Ding; Siobán D Harlow; John F Randolph; Antonia M Calafat; Bhramar Mukherjee; Stuart Batterman; Ellen B Gold; Sung Kyun Park
Journal:  J Clin Endocrinol Metab       Date:  2020-09-01       Impact factor: 5.958

Review 7.  Endocrine disruptors and the breast: early life effects and later life disease.

Authors:  Madisa B Macon; Suzanne E Fenton
Journal:  J Mammary Gland Biol Neoplasia       Date:  2013-02-17       Impact factor: 2.673

Review 8.  Cosmetics use and age at menopause: is there a connection?

Authors:  Erika T Chow; Shruthi Mahalingaiah
Journal:  Fertil Steril       Date:  2016-08-18       Impact factor: 7.329

9.  Determinants of per- and polyfluoroalkyl substances (PFAS) in midlife women: Evidence of racial/ethnic and geographic differences in PFAS exposure.

Authors:  Sung Kyun Park; Qing Peng; Ning Ding; Bhramar Mukherjee; Siobán D Harlow
Journal:  Environ Res       Date:  2019-05-18       Impact factor: 6.498

10.  Disruption of reproductive aging in female and male rats by gestational exposure to estrogenic endocrine disruptors.

Authors:  Deena M Walker; Bailey A Kermath; Michael J Woller; Andrea C Gore
Journal:  Endocrinology       Date:  2013-04-16       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.